soul trial semaglutide cardiovascular outcomes semaglutide reduces MACEs primarily by a reduction in CV-related deaths - Oralsemaglutideandcardiovascular outcomesin high risk type 2 diabetes designed to assess the cardiovascular efficacy of oral semaglutide SOUL Trial: Oral Semaglutide Demonstrates Significant Cardiovascular Benefits

Oralsemaglutideandcardiovascular outcomesin high risk type 2 diabetes The SOUL trial (Semaglutide Cardiovascular Outcomes Trial) has provided compelling evidence regarding the cardiovascular efficacy of oral semaglutide, a groundbreaking medication for individuals with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), or both.Effects of oral semaglutide on heart failure outcomes in people ... This phase 3b cardiovascular outcomes trial was designed to assess the cardiovascular efficacy of oral semaglutide and has yielded significant results, found a lower risk of cardiovascular events with oral semaglutide compared to placebo.

The SOUL trial is a large-scale, randomized, double-blind, parallel-group, placebo-controlled CV outcomes trial that randomized 9650 participants with type 2 diabetes.2025年4月10日—In conclusion, the SOUL trial highlights thatoral semaglutide reduces cardiovascular risk in T2D patients, regardless of concurrent SGLT2i use. The primary objective was to determine if oral semaglutide could reduce the incidence of major adverse cardiovascular events (MACE). The trial achieved its primary endpoint, demonstrating a significant reduction in risk作者：R Pop-Busui—The SOUL trial was a double-blind, randomized, placebo-controlled, event-driven,phase 3b cardiovascular outcomes trialconducted at 444 centers ....

Key Findings and Efficacy:

A consistent and impactful finding from the SOUL trial is the 14% reduction in the risk of MACE observed with oral semaglutide versus placebo.Oral Semaglutide Therapy Reduces Cardiovascular Events ... This reduction encompasses several critical cardiovascular endpoints, including cardiovascular death, non-fatal heart attacks, and non-fatal strokes2025年6月10日—METHODS: The SOUL trial (Semaglutide Cardiovascular Outcomes Trial; NCT03914326)randomized 9650 participants with type 2 diabetesand .... Specifically, oral semaglutide improved each of the composite measures, contributing to a more robust cardiovascular profile for patients. Further analysis revealed that oral semaglutide reduces the risk of heart attack, stroke, and cardiovascular death by 14%.

The study also explored the impact of concomitant treatmentsOral Semaglutide and Cardiovascular Outcomes in High .... Notably, oral semaglutide reduced major adverse cardiovascular event outcomes independently of concomitant SGLT2i treatment, and this combination appeared to be safe.SOUL results indicate oral semaglutide reduces MACE risk ... This finding suggests that oral semaglutide offers cardiovascular benefits that are not solely dependent on other commonly used diabetes medications like SGLT2 inhibitors. This underscores the versatile cardiovascular advantages of semaglutideOral semaglutide reduced major adverse cardiovascular event outcomesindependently of concomitant SGLT2i treatment, and this combination appeared to be safe..

Further prespecified analyses of the SOUL Randomized Trial indicated that the CV benefits of oral semaglutide appeared more pronounced with higher HbA1c levels at baseline but remained consistent across various patient subgroups. This suggests that oral semaglutide reduces cardiovascular risk in T2D patients, regardless of their baseline glycemic control within the studied population.

Safety and Tolerability:

In terms of safety, the SOUL trial reported a manageable safety profile.作者：I Jialal·2025·被引用次数：1—In this largetrial, oralsemaglutidetherapy resulted in a 14% relative risk reduction in major ASCVD events compared to placebo in T2DM patents with ASCVD, ... The incidence of serious adverse events was 47.Effects of oral semaglutide on cardiovascular outcomes in ...9% in the oral semaglutide group and 50.2025年3月29日—TheSOUL trialshowed that in patients with T2DM and ASCVD, CKD, or both, use of oralsemaglutidewas associated with a significantly lower risk ...3% in the placebo groupOral Semaglutide and Cardiovascular Outcomes in People .... This indicates that oral semaglutide was well-tolerated by the participants, with a safety profile comparable to placebo in this high-risk population.Oral Semaglutide and Cardiovascular Outcomes

Impact on Heart Failure:

Beyond the primary MACE endpoints, the SOUL trial also aimed to evaluate the effect of oral semaglutide versus placebo on heart failure (HF) outcomes. While the full extent of these findings is being explored, preliminary results and related research suggest a positive impact on heart failure outcomes, further bolstering the cardiovascular benefits of this semaglutide formulation.SOUL: Oral Semaglutide Bests Usual Care in High-Risk ...

Expert Endorsements and Future Implications:

The results of the SOUL trial have garnered significant attention within the medical community2025年6月10日—Oral semaglutide reduced major adverse cardiovascular event outcomesindependently of concomitant SGLT2i treatment, and this combination appeared to be safe.. Researchers like DK McGuire and N Marx have been instrumental in presenting and analyzing these findings, highlighting the cardiovascular benefits beyond glycemic control that semaglutide offers. The SOUL trial results indicate oral semaglutide reduces MACE risk, with semaglutide reduces MACEs primarily by a reduction in CV-related deaths, offering a new paradigm in managing cardiovascular risk in individuals with type 2 diabetesSOUL trial shows oral semaglutide has positive CV ....

The publication of SOUL trial semaglutide results in esteemed scientific journals, including potential appearances in the SOUL trial NEJM or similar high-impact publications, is anticipated to further solidify its place in clinical practice. The SOUL trial summary of these findings emphasizes that oral semaglutide offers meaningful cardiovascular benefits and represents a significant advancement in the treatment of patients with elevated cardiovascular risk.SOUL: Oral Semaglutide Bests Usual Care in High-Risk ...

In conclusion, the SOUL trial has definitively established oral semaglutide as a valuable therapeutic option for reducing cardiovascular events in adults with type 2 diabetes and high cardiovascular riskOral Semaglutide and Cardiovascular Outcomes in People .... Its efficacy in reducing MACE, coupled with a favorable safety profile, positions oral semaglutide as a crucial tool in comprehensive cardiovascular risk managementOral Semaglutide and Heart Failure Outcomes in Persons ....